Enliven Therapeutics, Inc. 4

Insider Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics, Inc. (ELVN) common stock on June 5, 2026 under a Rule 10b5-1 trading plan for roughly $346,000 in total proceeds.

On June 5, 2026, Lori Anne Kunkel, an insider of Enliven Therapeutics, Inc., sold a total of 10,000 shares of the company’s common stock in three open-market transactions pursuant to a pre-established Rule 10b5-1 trading plan. The sales were executed at weighted-average prices of $34.2794 for 7,779 shares, $35.3573 for 1,867 shares, and $35.8187 for 354 shares, implying aggregate proceeds of approximately $346,000. Following these transactions, she held 51,884 shares directly, with an additional indirect position noted in the footnotes related to the Lori Kunkel Revocable Trust, from which 31,172 shares had been previously transferred to her; the filing emphasizes that all trades were part of a planned selling program and that the reported prices reflect weighted averages over multiple execution prices within specified ranges.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

sec

Accession

0001536368-26-000004

Alert Tier

6